Riskpilot← Back to searchSign inGet full accessAcuCort AB
ABActiveOrg 5567155113LundResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20065-9 employees
Revenue 2024
SEK 675K
EBITDA margin
-2031.3%
-3% vs 2023
Equity ratio
90.2%
Financial strength
Net profit 2024
SEK -17,4M
-27% vs 2023
| Revenue | SEK 675K | — |
| EBITDA | SEK -13,7M | -3% |
| Net profit | SEK -17,4M | -27% |
| Total assets | SEK 45,3M | -23% |
| Equity | SEK 40,8M | -14% |
| Employees | — | — |
Legal name
AcuCort AB
Org number
5567155113
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
15 november 2006
Share capital
SEK 45 284 000
Employees
5-9
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska, direkt eller indirekt, bedriva forskning, utveckling, utbildning, marknadsföring och försäljning inom det medicinska området samt idka därmed förenlig verksamhet.
Address
Lund
Phone
+4642387418
Email
jonas.jonmark@acucort.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 675 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −2 179 | −1 920 | −4 669 | −6 221 | −8 370 | −7 749 | −11 295 | −14 825 | −13 249 | −13 711 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −3 674 |
| EBIT | −2 179 | −1 920 | −4 669 | −6 221 | −8 370 | −7 749 | −11 295 | −14 825 | −13 249 | −17 385 |
| Net financials | — | −26 | 8 | 1 | 1 | −17 | −26 | 36 | −443 | −13 |
| Profit before tax | −2 179 | −1 946 | −4 661 | −6 220 | −8 369 | −7 766 | −11 321 | −14 789 | −13 691 | −17 398 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −2 179 | −1 946 | −4 661 | −6 220 | −8 369 | −7 766 | −11 321 | −14 789 | −13 691 | −17 398 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 20 215 | 24 175 | 31 491 | 36 412 | 55 984 | 47 299 | 63 198 | 49 704 | 58 507 | 45 272 |
| Equity | 19 725 | 23 576 | 29 751 | 34 511 | 53 966 | 46 200 | 60 370 | 45 581 | 47 532 | 40 849 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 490 | 599 | 1 740 | 1 901 | 2 018 | 1 099 | 2 828 | 4 123 | 10 975 | 4 423 |
| Total debt | 490 | 599 | 1 740 | 1 901 | 2 018 | 1 099 | 2 828 | 4 123 | 10 975 | 4 423 |
EBITDA margin
-2031.3%
This company
15.8%
Market median
-12956% vs market
20152024
Equity ratio
90.2%
This company
38.2%
Market median
+136% vs market
20152024
Return on equity
-42.6%
This company
18.4%
Market median
-332% vs market
20152024
Net profit margin
-2577.5%
This company
8.1%
Market median
-31921% vs market
20152024
Asset turnover
0.01×
This company
1.12×
Market median
-99% vs market
20152024
Debt / equity
0.11×
This company
0.62×
Market median
+82% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AU Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
SJ Chief Executive Officer | Chief Executive Officer | 2021 | — | — |
AO Chief Auditor | Chief Auditor | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2025 | — | — | |
| Chairman | 2020 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2020 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of AcuCort AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ann Ulrika Gidner | Chief Executive Officer | 0 companies |
| Sven Jonas Jönmark | Chief Executive Officer | 0 companies |
| Anders Ola Bjärehäll | Chief Auditor | 0 companies |
| Leif Göran Kvist | Board of Directors | 0 companies |
| Lilly Alexandra Monica Johnsson | Board of Directors | 0 companies |
| Anna Maria Albertina Eriksrud | Board of Directors | 0 companies |
| Jan Søren Poulsen | Board of Directors | 0 companies |
| Ebba Cecilia Margareta Fåhraeus | Chairman | 0 companies |
| Helen Cecilia Ljungdahl Round | Board of Directors | 0 companies |
| Nils Göran Tornling | Board of Directors | 0 companies |
| Monica Kristina Wallter | Board of Directors | 0 companies |